Excess all-cause mortality in the evaluation of a screening trial to account for selective participation

Journal of Medical Screening

Volumn 20, Issue 1, 2013, Pages 39-45

  Kranse, Ries ^a,b   van Leeuwen, Pim J ^a   Hakulinen, Timo ^c   Hugosson, Jonas ^d   Tammela, Teuvo L ^e   Ciatto, Stefano ^f   Roobol, Monique J ^a   Zappa, Marco ^g   Aus, Gunar ^d   Bangma, Chris H ^a   Moss, Sue M ^h   Auvinen, Anssi ⁱ   Schroder, Fritz H ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Netherlands Comprehensive Cancer Organisation   (Netherlands)

^c FINNISH CANCER REGISTRY   (Finland)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f Azienda Ospedaliero Universitaria Careggi   (Italy)

^g Institute for Cancer Prevention   (Italy)

^h Haematology Evaluation   (United Kingdom)

ⁱ TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; HUMAN; MALE; MASS SCREENING; METHODOLOGY; MORTALITY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; PROCEDURES; PROSTATIC NEOPLASMS;

EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 84890161301     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1177/0969141312474443     Document Type: Article

References (13)

1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328
2. De Koning HJ, Blom J, Merkelbach JW, et al. Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU Int 2003;92(Suppl. 2):71-78
3. Lenner P. The excess mortality rate. A useful concept in cancer epidemiology. Acta Oncol 1990;29:573-576
4. van Leeuwen PJ, Kranse R, Hakulinen T, et al. Disease specific mortality may underestimate the total effect of prostate cancer screening. J Med Screen 2010;17:204-210
5. Finne P, Stenman UH, Määttänen L, et al. The Finnish trial of prostate cancer screening: where are we now? BJU Int 2003;92(Suppl. 2):22-6
6. Ciatto S, Gervasi G, Frullini P, et al. Specific features of the Italian section of the ERSPC. BJU Int 2003;92(Suppl. 2):30-32
7. Hugosson J, Aus G, Bergdahl S, et al. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU Int 2003;92(Suppl. 2):39-43
8. Schörder FH, Denis LJ, Roobol M, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003;92(Suppl. 2):1-13
9. Rabe-Hesketh S, Everitt B. A handbook of statistical analyses using Stata. Boca Raton, FL Chapman & Hall/CRC, 2000
10. University of California Berkeley (USA) and Max Planck Institute for Demographics Research (Germany). The Human Mortality Database. Available at: http:// www.mortality.org/ (last checked January 2011)
11. Black WC. Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst 2000; 92:1280-1282
12. American Cancer Society. Lifetime Risk of Developing or Dying From Cancer. Available at: http:// www.cancer.org/Cancer/CancerBasics/ lifetime-probability-ofdeveloping-or-dying-from-cancer (last checked June 2011)
13. Bergdahl AG, Aus G, Lilja H, et al. Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees. Cancer 2009;115:5672-5679